Biotech News

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid (PYPD)PolyPid2026-07-29 12:30 ESTFDA / regulatory

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million milestone payment, completing $30 million in upfront and near-term milestone payments under recently

Related news

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-03-31 12:30 EST

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

View all latest news

PolyPid

Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over days or weeks. D-PLEX100 D-PLEX100 delivers doxycycline locally after...

Recent company news

PYPDPolyPid2026-07-30 12:00 EST

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PYPDPolyPid2026-07-29 12:30 EST

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PYPDPolyPid2026-07-21 11:30 EST

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-05-20 12:30 EST

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

Stock data

Close: 4.81 USD
Market cap: 93.38M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States